The (epi)genomic landscape of splenic marginal zone lymphoma, biological implications, clinical utility, and future questions

Abstract

Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoma comprising less than 2% of lymphoid neoplasms. Approximately 70% of patients have a progressive disease requiring treatment and up to 30% of patients relapse or transform to diffuse large B-cell lymphoma. Whilst research over the last decade has transformed our understanding of many B-cell tumours, it is only beginning to shed light on the molecular pathogenesis of SMZL. Expansive immunogenetic investigations have shown biases in the immunoglobulin gene repertoire with distinct patterns of somatic hypermutation, suggesting a pathogenic role for antigen selection. In parallel cytogenetic studies have found a number of recurrent chromosomal lesions, in particular a deletion of the long arm of chromosome 7, though causative genes have not been identified. Our understanding of the mutational landscape of SMZL is built on a limited number of index cases, but has highlighted recurrent mutations in KLF2, NOTCH2 and TP53, and a spectrum of genes that cluster within biological pathways of importance in B-cell differentiation. While preliminary DNA methylation profiling has shown epigenetically distinct patient sub-groups, including a group defined by elevated expression of polycomb repressor complex 2 components. This review will provide an overview of our current understanding of the molecular basis of SMZL, and how this information impacts patient outcomes. Furthermore, we will outline; (1) the knowledge gaps that still exist; (2) a potential future research direction; and (3) how a detailed molecular understanding of the disease will ultimately provide patients with improved management and treatment choices.

Keywords

Splenic marginal zone lymphoma / pathogenesis / genetics / epigenetics / clinical

References

[1] SwerdlowSH,PileriSA.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood2016;127:2375-90 PMCID:PMC4874220

[2] KanellisG,Montes-MorenoS.Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.Haematologica2010;95:1122-9 PMCID:PMC2895036

[3] Traverse-GlehenA,SallesG,FelmanP.Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity.Discov Med2012;13:253-65

[4] XochelliA,GardinerA.Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?.Blood2014;123:1199-206

[5] MerliM,BertùL.Clonal B-cell lymphocytosis with mariginal-zone features: comparison with overt splenic marginal-zone lymphomas in 77 patients from a monocentric series.Blood2019;134:4017

[6] ChacónJI,MuñozE,MateoM.Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients.Blood2002;100:1648-54

[7] MatutesE,MontalbanC.Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.Leukemia2008;22:487-95

[8] ZuccaE,BuskeC.ESMO Guidelines CommitteeElectronic address: [e-mail]. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2020;31:17-29

[9] LumishM,ImberBS,vonKeudell G.How we treat mature B-cell neoplasms (indolent B-cell lymphomas).J Hematol Oncol2021;14:5 PMCID:PMC7789477

[10] ArcainiL,PaulliM.Splenic marginal zone lymphoma: from genetics to management.Blood2016;127:2072-81

[11] MeloJV,ParreiraA,LampertIA.Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens.J Clin Pathol1987;40:642-51 PMCID:PMC1141055

[12] MulliganSP,DeardenC.Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases.Br J Haematol1991;78:206-9

[13] SchmidC,DissT.Splenic marginal zone cell lymphoma.Am J Surg Pathol1992;16:455-66

[14] BaldiniL,CroL.Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin.Blood1994;84:270-8

[15] ZhuD,StevensonFK.Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes.Blood1995;85:1603-7

[16] MollejoM,LloretE.Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases.Am J Surg Pathol1995;19:1146-57

[17] HermineO,BronowickiJP.Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.N Engl J Med2002;347:89-94

[18] NovakU,KweeI.The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.Blood2009;113:4918-21 PMCID:PMC2686142

[19] OscierDG,GardinerA.Cytogenetic studies in splenic lymphoma with villous lymphocytes.Br J Haematol1993;85:487-91

[20] BikosV,HadzidimitriouA.Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.Leukemia2012;26:1638-46

[21] XochelliA,PolychronidouE.Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.J Pathol2019;247:416-21

[22] BikosV,StalikaE.An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.Clin Cancer Res2016;22:2032-40

[23] ClipsonA,deLeval L.KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.Leukemia2015;29:1177-85

[24] ParryM,LjungströmV.Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.Clin Cancer Res2015;21:4174-83 PMCID:PMC4490180

[25] ArribasAJ,MensahAA.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Blood2015;125:1922-31 PMCID:PMC4416938

[26] ArribasAJ.Methylation patterns in marginal zone lymphoma.Best Pract Res Clin Haematol2017;30:24-31

[27] HamblinTJ,GardinerA,StevensonFK.Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood1999;94:1848-54

[28] DamleRN,FaisF.Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia.Blood1999;94:1840-7

[29] RinaldiA,ChigrinovaE.Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.Blood2011;117:1595-604

[30] ArcainiL,PassamontiF.Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.Blood Cells Mol Dis2009;42:286-91

[31] SalidoM,OscierD.Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.Blood2010;116:1479-88

[32] RossiD,Dominguez-SolaD.Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.Blood2011;118:4930-4

[33] PivaR,FamàR.The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.Leukemia2015;29:503-7

[34] DavoliT,MengwasserKE.Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.Cell2013;155:948-62 PMCID:PMC3891052

[35] SackLM,LiMZ.Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns.Cell2018;173:499-514.e23 PMCID:PMC6643283

[36] WatkinsAJ,YeH.Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.J Pathol2010;220:461-74

[37] AlgaraP,Sanchez-BeatoM.Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course.Blood2002;99:1299-304

[38] FresquetV,ParkerA.High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.Br J Haematol2012;158:712-26

[39] HosonoN,MahfouzR.Recurrent genetic defects on chromosome 5q in myeloid neoplasms.Oncotarget2017;8:6483-95 PMCID:PMC5351647

[40] VenugopalS,SteensmaDP.Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Blood Rev2021;46:100735

[41] DierlammJ,StulM.Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization.Leukemia1997;11:747-58

[42] DierlammJ,WlodarskaI.Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybridization.Br J Haematol1996;93:242-9

[43] HernándezJM,GutiérrezNC.Novel genomic imbalances in B-Cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.Am J Pathol2001;158:1843-50 PMCID:PMC1891967

[44] SoléF,FlorensaL.Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma.Br J Haematol1997;98:446-9

[45] TroussardX,Radford-WeissI.Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Français d'Hématologie Cellulaire (GFHC) study.Br J Haematol1998;101:712-21

[46] RobledoC,BenitoR.Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas.PLoS One2011;6:e24939 PMCID:PMC3177857

[47] GailllardB,LeQH.Groupe Francophone de Cytogénétique HématologiqueClinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.Br J Haematol2021;193:72-82

[48] HoangPH,CornishAJ.Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.Leukemia2018;32:2459-70 PMCID:PMC6224406

[49] BurnsA,BecqJ.Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.Leukemia2018;32:332-42 PMCID:PMC5808074

[50] ArthurSE,GrandeBM.Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.Nat Commun2018;9:4001 PMCID:PMC6167379

[51] QuesadaV,VillamorN.Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.Nat Genet2011;44:47-52

[52] PuenteXS,QuesadaV.Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.Nature2011;475:101-5 PMCID:PMC3322590

[53] Oquendo C, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC. Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.Sci Rep2019;9:10444 PMCID:PMC6639539

[54] KielMJ,BetzBL.Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.J Exp Med2012;209:1553-65 PMCID:PMC3428949

[55] LuijtenMNH,CrastaKC.Mutational game changer: Chromothripsis and its emerging relevance to cancer.Mutat Res2018;777:29-51

[56] ParryM,GibsonJ.Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.PLoS One2013;8:e83244 PMCID:PMC3862727

[57] RossiD,FangazioM.The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.J Exp Med2012;209:1537-51 PMCID:PMC3428941

[58] Campos-MartínY,Martínez-LópezA.Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.Haematologica2017;102:e310-2 PMCID:PMC5541884

[59] JalladesL,SujobertP.Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.Haematologica2017;102:1758-66 PMCID:PMC5622860

[60] FeinbergMW,FischS.An emerging role for Krüppel-like factors in vascular biology.Trends Cardiovasc Med2004;14:241-6

[61] DangDT,YangVW.The biology of the mammalian Krüppel-like family of transcription factors.Int J Biochem Cell Biol2000;32:1103-21 PMCID:PMC2754176

[62] HartGT,HogquistKA.Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression.Proc Natl Acad Sci U S A2011;108:716-21 PMCID:PMC3021025

[63] WinkelmannR,PorstnerM.B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2.Proc Natl Acad Sci U S A2011;108:710-5 PMCID:PMC3021026

[64] HoekKL,CollinsPL.Follicular B cell trafficking within the spleen actively restricts humoral immune responses.Immunity2010;33:254-65 PMCID:PMC2929658

[65] RentzschP,CooperGM,KircherM.CADD: predicting the deleteriousness of variants throughout the human genome.Nucleic Acids Res2019;47:D886-94 PMCID:PMC6323892

[66] TanigakiK,YamamotoN.Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells.Nat Immunol2002;3:443-50

[67] SaitoT,IchikawaM.Notch2 Is Preferentially Expressed in Mature B Cells and Indispensable for Marginal Zone B Lineage Development.Immunity2003;18:675-85

[68] ArrugaF,DeaglioS.The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies.Front Oncol2018;8:550 PMCID:PMC6275466

[69] MoranST,LiuH.Synergism between NF-kappa B1/p50 and Notch2 during the development of marginal zone B lymphocytes.J Immunol2007;179:195-200

[70] KopanR.Notch signaling.Cold Spring Harb Perspect Biol2012;4:a011213 PMCID:PMC3475170

[71] RadtkeF,MacDonaldHR.Notch signaling in T- and B-cell development.Curr Opin Immunol2004;16:174-9

[72] MartínezN,VaquéJP.Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.Leukemia2014;28:1334-40

[73] ShanmugamV,HiltonLK.Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.Blood Adv2021;5:71-83 PMCID:PMC7805321

[74] HampelF,HojerC.CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling.Blood2011;118:6321-31

[75] FabbriG,ViganottiM.Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A2017;114:E2911-9 PMCID:PMC5389283

[76] KimMP.Mutant p53 partners in crime.Cell Death Differ2018;25:161-8 PMCID:PMC5729539

[77] PillaiS.The follicular versus marginal zone B lymphocyte cell fate decision.Nat Rev Immunol2009;9:767-77

[78] SpinaV.NF-κB deregulation in splenic marginal zone lymphoma.Semin Cancer Biol2016;39:61-7

[79] LimKH,StaudtLM.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Immunol Rev2012;246:359-78 PMCID:PMC4094296

[80] YanQ,WatkinsAJ.BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.Haematologica2012;97:595-8 PMCID:PMC3347666

[81] PillonelV,NgCKY.High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.Leukemia2018;32:2412-26 PMCID:PMC6224405

[82] NgoVN,SchmitzR.Oncogenically active MYD88 mutations in human lymphoma.Nature2011;470:115-9 PMCID:PMC5024568

[83] LunningMA.Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.Blood Cancer J2015;5:e361 PMCID:PMC4635197

[84] SpinaV,MessinaM.The genetics of nodal marginal zone lymphoma.Blood2016;128:1362-73 PMCID:PMC5016706

[85] FroimchukE,GeK.Histone H3 lysine 4 methyltransferase KMT2D.Gene2017;627:337-42 PMCID:PMC5546304

[86] ZhangJ,HusseinS.Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.Nat Med2015;21:1190-8 PMCID:PMC5145002

[87] GreenMR,LiuCL.Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.Proc Natl Acad Sci U S A2015;112:E1116-25 PMCID:PMC4364211

[88] OkosunJ,WangJ.Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.Nat Genet2014;46:176-81 PMCID:PMC3907271

[89] PhanRT.The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.Nature2004;432:635-9

[90] HanL,MayakondaA.Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice.Leukemia2019;33:2291-305 PMCID:PMC6756219

[91] TrøenG,JenssenT.Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-Cell transcription factor notch2 in splenic marginal zone lymphoma.J Mol Diagn2004;6:297-307 PMCID:PMC1867488

[92] Ruiz-BallesterosE,RodriguezA.Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.Blood2005;106:1831-8

[93] NavarroA,Martínez-TrillosA.Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.Haematologica2017;102:e360-3 PMCID:PMC5685223

[94] RobinsonJE,BouskaAC,CutucacheCE.Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential.Front Oncol2020;10:640 PMCID:PMC7225304

[95] Duran-ferrerM,NadeuF.The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome.Nat Cancer2020;1:1066-81

[96] QueirósAC,Vilarrasa-BlasiR.Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.Cancer Cell2016;30:806-21 PMCID:PMC5805090

[97] KulisM,HeathS.Whole-genome fingerprint of the DNA methylome during human B cell differentiation.Nat Genet2015;47:746-56 PMCID:PMC5444519

[98] KulisM,BibikovaM.Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.Nat Genet2012;44:1236-42

[99] LeeST,FominME.Epigenetic remodeling in B-cell acute lymphoblastic leukemia occurs in two tracks and employs embryonic stem cell-like signatures.Nucleic Acids Res2015;43:2590-602 PMCID:PMC4357708

[100] SuIH,KrutchinskyAN.Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement.Nat Immunol2003;4:124-31

[101] AkasakaT,KawahiraH.The Role of mel-18, a Mammalian Polycomb Group Gene, during IL-7-Dependent Proliferation of Lymphocyte Precursors.Immunity1997;7:135-46

[102] OakesCC,AssenovY.DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.Nat Genet2016;48:253-64 PMCID:PMC4963005

[103] ZillerMJ,MüllerF.Charting a dynamic DNA methylation landscape of the human genome.Nature2013;500:477-81 PMCID:PMC3821869

[104] JiangY,ShaknovichR.Mechanisms of epigenetic deregulation in lymphoid neoplasms.Blood2013;121:4271-9 PMCID:PMC3663422

[105] SoléC,LawrieCH.MicroRNAs as Biomarkers of B-cell Lymphoma.Biomark Insights2018;13:1177271918806840 PMCID:PMC6195009

[106] WatkinsAJ,ZengN.An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma.PLoS One2012;7:e44997 PMCID:PMC3441634

[107] Ruiz-BallesterosE,MateoM,MartínezP.MicroRNA losses in the frequently deleted region of 7q in SMZL.Leukemia2007;21:2547-9

[108] KaraayvazM,JuJ.miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.Cell Death Dis2013;4:e659 PMCID:PMC3702282

[109] ScarolaM,SchneiderC.miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response.Cancer Res2010;70:6925-33

[110] DiLisio L,Gómez-LópezG.MicroRNA signatures in B-cell lymphomas.Blood Cancer J2012;2:e57 PMCID:PMC3288280

[111] BouteloupM,RachinelN.MicroRNA expression profile in splenic marginal zone lymphoma.Br J Haematol2012;156:279-81

[112] Peveling-OberhagJ,SchmidtA. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012;26:1654-62.

[113] CervettiG,SordiE.Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).Ann Oncol2010;21:851-4

[114] PhillipsTJ,GurionR.Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204).Blood2020;136:27-8

[115] OpatS,LintonK.Efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: initial results of the MAGNOLIA (BGB-3111-214) trial.Blood2020;136:28-30

[116] ZinzaniP,JurczakW.Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 study.Hematol Oncol2019;37:182-3

[117] NoyA,ColemanM.Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.Blood Adv2020;4:5773-84 PMCID:PMC7686907

[118] PanayiotidisP,MollicaL.Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.Blood Adv2021;5:823-8 PMCID:PMC7876879

[119] TarantelliC,GaudioE.Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.Blood Adv2020;4:819-29 PMCID:PMC7065481

[120] ArribasAJ,CascioneL.Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma.Blood Cancer Discovery2020;

[121] Andrade-camposMM,Sanchez-gonzalezB.Assessment of cell-free DNA (cfDNA) in 221 patients with lymphoproliferative malignancies at diagnosis and during follow-up.Blood2019;134:492

[122] RossiD,SpaccarotellaE.Diffuse large B-cell lymphoma genotyping on the liquid biopsy.Blood2017;129:1947-57

[123] ZhouW,RamjanZ.DNA methylation loss in late-replicating domains is linked to mitotic cell division.Nat Genet2018;50:591-602 PMCID:PMC5893360

[124] LeBris Y,GuièzeR.Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.Hematol Oncol2017;35:664-70

[125] ThompsonPA,WierdaWG.Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.Cancer2015;121:3612-21 PMCID:PMC4866653

[126] GreenwellIB,LeeMJ.Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.Cancer2018;124:2306-15 PMCID:PMC5992038

[127] AndersonMA,LewTE.Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.Blood2017;129:3362-70

[128] BrownJR,O'BrienS.Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.Leukemia2018;32:83-91 PMCID:PMC5770586

[129] GisselssonD,HöglundM.Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity.Proc Natl Acad Sci U S A2000;97:5357-62 PMCID:PMC25833

[130] BarthelFP,TangM.Systematic analysis of telomere length and somatic alterations in 31 cancer types.Nat Genet2017;49:349-57 PMCID:PMC5571729

[131] RampazzoE,TrentinL.Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.Haematologica2012;97:56-63 PMCID:PMC3248931

[132] StreffordJC,ForsterJ.Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Leukemia2015;29:2411-4 PMCID:PMC4676082

[133] ParkerAE,DavisZ.Telomere length by Tel-PCR in B cell malignancies.Blood2005;106:2955

[134] CawthonRM.Telomere measurement by quantitative PCR.Nucleic Acids Res2002;30:e47 PMCID:PMC115301

[135] BairdDM,Wynford-ThomasD.Extensive allelic variation and ultrashort telomeres in senescent human cells.Nat Genet2003;33:203-7

[136] LaiTP,NohJ.A method for measuring the distribution of the shortest telomeres in cells and tissues.Nat Commun2017;8:1356 PMCID:PMC5676791

[137] KahlVFS,NelsonCB.Telomere Length Measurement by Molecular Combing.Front Cell Dev Biol2020;8:493 PMCID:PMC7308456

[138] BruscagginA,TapiaG.Multi-omics landscape of splenic marginal zone lymphoma (SMZL) - interim analysis of IELSG46 study.Hematol Oncol2019;37:181-2

[139] GuidettiF,FrigeniM.Molecular subtypes of splenic marginal zone lymphoma (SMZL) are associated with distinct pathogenic mechanisms and outcomes - interim analysis of the IELSG46 study.Blood2018;132:922